Perospirone (Lullan) is an atypical antipsychotic of the azapirone family. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.
Perospirone acts as a 5-HT1A receptor partial agonist, 5-HT2A receptor inverse agonist, and D2, D4, and α1-adrenergic receptor antagonist.